Clinical Trial Update: Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

Phase 3 study characterizing 24-hour spirometry profiles of inhaled BI 1744 CL versus inhaled formoterol (Foradil) in patients with chronic obstructive pulmonar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BI 1744 CL
• Foradil (formoterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-07-01